Dr Azita Simoni, MD | |
425 Haaland Dr Ste 204, Thousand Oaks, CA 91361-5231 | |
(805) 497-8080 | |
(805) 497-8806 |
Full Name | Dr Azita Simoni |
---|---|
Gender | Female |
Speciality | Dermatology |
Experience | 24 Years |
Location | 425 Haaland Dr Ste 204, Thousand Oaks, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366418931 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | A101945 (California) | Primary |
207N00000X | Dermatology | 224015 (New York) | Secondary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Csi Medical Group | 5890916845 | 103 |
News Archive
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
States that have expanded Medicaid eligibility under the Affordable Care Act have seen an "early surge in demand" for hip and knee replacement surgery, reports a study in the September 2, 2020 issue of The Journal of Bone & Joint Surgery.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.
› Verified 8 days ago
Entity Name | Skin And Beauty Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073751129 PECOS PAC ID: 8628170347 Enrollment ID: O20070227000738 |
News Archive
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
States that have expanded Medicaid eligibility under the Affordable Care Act have seen an "early surge in demand" for hip and knee replacement surgery, reports a study in the September 2, 2020 issue of The Journal of Bone & Joint Surgery.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.
› Verified 8 days ago
Entity Name | Csi Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871909804 PECOS PAC ID: 5890916845 Enrollment ID: O20141016001930 |
News Archive
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
States that have expanded Medicaid eligibility under the Affordable Care Act have seen an "early surge in demand" for hip and knee replacement surgery, reports a study in the September 2, 2020 issue of The Journal of Bone & Joint Surgery.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Azita Simoni, MD 50 N La Cienega Blvd, Suite 150, Beverly Hills, CA 90211-2227 Ph: (310) 889-4882 | Dr Azita Simoni, MD 425 Haaland Dr Ste 204, Thousand Oaks, CA 91361-5231 Ph: (805) 497-8080 |
News Archive
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
InSightec Ltd, the global leader in MR guided focused ultrasound, announced that the first patient has been treated as part of an ExAblate Neuro Phase III pivotal trial. The trial is a multicenter, double-blinded, randomized study to evaluate the efficacy and safety of treatment using the ExAblate Neuro in medication-refractory essential tremor patients.
States that have expanded Medicaid eligibility under the Affordable Care Act have seen an "early surge in demand" for hip and knee replacement surgery, reports a study in the September 2, 2020 issue of The Journal of Bone & Joint Surgery.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.
› Verified 8 days ago
Dr. Seth R Stevens, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 267 W Hillcrest Dr, Thousand Oaks, CA 91360 Phone: 805-497-1694 Fax: 805-373-7493 | |
Dr. Navid Ezra, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3095 Old Conejo Rd, Suite 200, Thousand Oaks, CA 91320 Phone: 805-222-5803 | |
Sean Condon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 267 W Hillcrest Dr, Thousand Oaks, CA 91360 Phone: 805-497-1694 | |
Dr. Jeanette Kamell Mitchell, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 55 Rolling Oaks Dr Ste 200, Thousand Oaks, CA 91361 Phone: 805-497-7529 Fax: 805-494-3486 | |
Robert A Gold, MD Dermatology Medicare: Medicare Enrolled Practice Location: 45 North Erbes Road, Thousand Oaks, CA 91362 Phone: 818-404-3200 | |
Dr. Nima Milani-nejad, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 100 Moody Ct Ste 200, Thousand Oaks, CA 91360 Phone: 805-418-3500 Fax: 805-418-3505 |